Media headlines about TrovaGene (NASDAQ:TROV) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TrovaGene earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 44.7850793158407 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several equities analysts recently weighed in on the company. Maxim Group set a $4.00 price objective on TrovaGene and gave the stock a “buy” rating in a research report on Wednesday, October 18th. HC Wainwright assumed coverage on TrovaGene in a research report on Thursday, December 21st. They set a “buy” rating and a $1.00 price objective for the company. Finally, cut TrovaGene from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $3.70.

Shares of TrovaGene (NASDAQ:TROV) traded up $0.01 on Friday, reaching $0.31. The company had a trading volume of 626,766 shares, compared to its average volume of 2,390,000. TrovaGene has a 1 year low of $0.23 and a 1 year high of $2.40. The company has a market capitalization of $16.32, a price-to-earnings ratio of -0.32 and a beta of 0.40.

TrovaGene (NASDAQ:TROV) last issued its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. The firm had revenue of $0.12 million for the quarter. equities analysts expect that TrovaGene will post -0.78 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at

About TrovaGene

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

Insider Buying and Selling by Quarter for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.